Sentynl Therapeutics has signed an agreement with PRG S&T to license Progerinin. Progerinin is an investigational molecule for the treatment of HGPS. HGPS is a rare genetic disease also known as progeria. The deal allows Sentynl Therapeutics to acquire the rights to further develop this molecule. The partnership includes joint research and potential commercial use of Progerinin. The goal is to provide a new treatment for patients with HGPS.